Compare Msci Inc (MSCI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs TG Therapeutics Inc — how do they compare? Msci Inc trades at $562.98 (market cap $45.51B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Msci Inc is far larger — about 5.5× TG Therapeutics Inc's market cap, and Msci Inc pays a 1.31% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MSCI | TGTX | |
|---|---|---|
Market Cap | $45.51B | $8.26B |
Sector | Financials | Health |
52-Week High | $643.83 | $59.06 |
52-Week Low | $511.84 | $26.39 |
Enterprise Value | $51.67B | $8.50B |
Dividend Yield | 1.31% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
